(S)-4-[(S)-5-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyrid in-4-yl)-2-methyl-2,3-d ihydrofuro[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid 2.2.2-trifluoro-1-methyl-ethyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-4-[(S)-5-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyrid in-4-yl)-2-methyl-2,3-d ihydrofuro[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid 2.2.2-trifluoro-1-methyl-ethyl ester
• 英文别名: (S)-4-[(S)-5-(1-Methanesulfonyl-1,2,3,6-tetrahydro-pyridin-4-yl)-2-methyl-2,3-dihydro-furo[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid 2,2,2-trifluoro-1-methyl-ethyl ester；[(2S)-1,1,1-trifluoropropan-2-yl] 4-[(2S)-2-methyl-5-(1-methylsulfonyl-3,6-dihydro-2H-pyridin-4-yl)-3H-furo[2,3-c]pyridin-2-yl]piperidine-1-carboxylate
• 化学式: C₂₃H₃₀F₃N₃O₅S
• 分子量: 517.57
• InChiKey: BAQPWLJKLFPZOJ-NYHFZMIOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  97.4
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (S)-5-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-methyl-2-piperidin-4-yl-2,3-dihydrofuro[2,3-c]pyridine 、 carbonic acid 4-nitro-phenyl ester (S)-2,2,2-trifluoro-1-methyl-ethyl ester 生成 (S)-4-[(S)-5-(1-methanesulfonyl-1,2,3,6-tetrahydro-pyrid in-4-yl)-2-methyl-2,3-d ihydrofuro[2,3-c]pyridin-2-yl]-piperidine-1-carboxylic acid 2.2.2-trifluoro-1-methyl-ethyl ester
  参考文献：
  名称：

  2,3-DIHYDROFURO[2,3-c]PYRIDIN-2-YLPIPERIDINE DERIVATIVES

  摘要：

  本发明涉及一般式I的化合物，其中R1、LQ和Ar基团的定义如申请书所述，具有有价值的药理学性质，特别是能够结合GPR119受体并调节其活性。

  公开号：

  US20130331410A1

文献信息

• [EN] 2,3-DIHYDRO-FURO[2,3-C]PYRIDIN-2-YL-PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF<br/>[FR] DÉRIVÉS DE 2,3-DIHYDRO-FURO[2,3-C]PYRIDIN-2-YL-PIPÉRIDINE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013186109A1

  公开（公告）日：2013-12-19

  The present invention relates to compounds of general formula (I), wherein the groups R1, LQ and Ar are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式(I)的化合物，其中基团R1、LQ和Ar如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• 2,3-dihydrofuro[2,3-c]pyridin-2-ylpiperidine derivatives
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08975277B2

  公开（公告）日：2015-03-10

  The present invention relates to compounds of general formula I, wherein the groups R1, LQ and Ar are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的化合物，其中R1、LQ和Ar基团如本申请所定义，具有有价值的药理特性，特别是能够与GPR119受体结合并调节其活性。
• 4-(2,3-Dihydro-furo[2,3-c]pyridin-2-yl)-piperidine-1-carboxylic acid ester derivatives as G-protein-coupled receptor 119 (GPR119) agonists for the treatment of metabolic disorders, such as diabetes, dyslipidemia and obesity
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2858996B1

  公开（公告）日：2016-12-07
• 2,3-DIHYDRO-FURO[2,3-C]PYRIDIN-2-YL-PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2858996A1

  公开（公告）日：2015-04-15
• US8975277B2
  申请人：——

  公开号：US8975277B2

  公开（公告）日：2015-03-10